IBRX ImmunityBio Inc
Price (delayed)
$3.62
Market cap
$2.52B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.97
Enterprise value
$3.39B
NantKwest (NASDAQ: NK) is an innovative, clinical-stage, immunotherapy company focused on harnessing the power of the innate immune system to treat cancer and infectious diseases. NantKwest is the leading producer
Highlights
ImmunityBio's revenue has surged by 121% YoY
The company's gross profit has surged by 121% YoY
ImmunityBio's net income has decreased by 26% YoY
The debt rose by 22% year-on-year and by 12% since the previous quarter
Key stats
What are the main financial stats of IBRX
Market
Valuations
Earnings
Shares outstanding
696.53M
Market cap
$2.52B
Enterprise value
$3.39B
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
1,901.16
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2,591.96
Revenue
$1.31M
EBIT
-$454.03M
EBITDA
-$430.32M
Free cash flow
-$425.62M
Per share
Balance sheet
Liquidity
EPS
-$0.97
Free cash flow per share
-$0.62
Book value per share
-$1.01
Revenue per share
$0
TBVPS
$0.62
Total assets
$444.33M
Total liabilities
$1.14B
Debt
$998.94M
Equity
-$698.39M
Working capital
$180.72M
Debt to equity
-1.43
Current ratio
3.91
Quick ratio
3.54
Net debt/EBITDA
-2.02
Margins
Efficiency
Dividend
EBITDA margin
-32,899%
Gross margin
100%
Net margin
-45,691.7%
Operating margin
-27,527.1%
Return on assets
-134.2%
Return on equity
N/A
Return on invested capital
-42.9%
Return on capital employed
-118.8%
Return on sales
-34,712.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
IBRX stock price
How has the ImmunityBio stock price performed over time
Intraday
0%
1 week
-2.16%
1 month
-20.26%
1 year
135.06%
YTD
-27.89%
QTD
-42.72%
Financial performance
How have ImmunityBio's revenue and profit performed over time
Revenue
$1.31M
Gross profit
$1.31M
Operating income
-$360.05M
Net income
-$597.65M
Gross margin
100%
Net margin
-45,691.7%
ImmunityBio's revenue has surged by 121% YoY
The company's gross profit has surged by 121% YoY
The net margin has surged by 77% since the previous quarter and by 43% year-on-year
ImmunityBio's operating margin has soared by 76% from the previous quarter and by 56% YoY
Growth
What is ImmunityBio's growth rate over time
Valuation
What is ImmunityBio stock price valuation
P/E
N/A
P/B
N/A
P/S
1,901.16
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2,591.96
ImmunityBio's EPS has increased by 15% YoY and by 11% QoQ
ImmunityBio's equity has decreased by 9% YoY
ImmunityBio's revenue has surged by 121% YoY
The P/S is 64% less than the last 4 quarters average of 5225.7 and 60% less than the 5-year quarterly average of 4805.3
Efficiency
How efficient is ImmunityBio business performance
ImmunityBio's return on sales has surged by 77% QoQ and by 44% YoY
The company's return on invested capital rose by 35% YoY and by 21% QoQ
IBRX's return on assets is up by 9% since the previous quarter and by 4.3% year-on-year
Dividends
What is IBRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for IBRX.
Financial health
How did ImmunityBio financials performed over time
The total assets is 61% less than the total liabilities
The total assets has soared by 53% YoY and by 11% from the previous quarter
ImmunityBio's total liabilities has increased by 22% YoY and by 4.6% from the previous quarter
The debt rose by 22% year-on-year and by 12% since the previous quarter
The company's debt to equity fell by 12% YoY and by 11% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.